We also demonstrate the potency of selective NOX2 inhibitor GSK2795039 in preventing toxic Aβ1-42 effects and propose NOX2 as a primary target for early interventions in Alzheimer’s disease, warranting further studies. This evidence concerns the gene CYBB and early-onset autosomal dominant Alzheimer disease.